Bliss GVS Pharma Open Offer: Anupam Rasayan to Acquire 26% Stake at ₹299/Share
Anupam Rasayan India Limited, along with Mates Visa Consultancy Private Limited, is making an Open Offer to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma Limited, representing 26.00% of the expanded voting share capital. The offer price is ₹299.00 per share. The offer opens on July 28, 2026, and closes on August 10, 2026.
An open offer to acquire a significant stake (26%) can lead to a change in control or substantial shareholding, which could impact the company's future strategy and operations. The offer price also sets a benchmark for the company's valuation.
The announcement is a procedural update regarding an open offer and does not inherently contain positive or negative news for the company itself, but rather for its shareholders who can participate in the offer.
Bliss GVS Pharma Limited has received a Letter of Offer dated July 18, 2026, from SBI Capital Markets Limited, acting as the Manager to the Open Offer for Anupam Rasayan India Limited (Acquirer) and its person acting in concert (PAC).
The Open Offer aims to acquire up to 2,77,26,848 equity shares, representing 26.00% of the expanded voting share capital of Bliss GVS Pharma Limited, at a price of ₹299.00 per equity share. This offer is made in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
The tentative schedule of activities for the offer includes the Offer Opening Date on July 28, 2026, and the Offer Closing Date on August 10, 2026. The maximum consideration for the offer, assuming full acceptance, is ₹829.03 crore.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.